LIVER TRANSPLANTATION WORLDWIDE COMMENTS
|
|
- Tabitha Franklin
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 13: , 2007 LIVER TRANSPLANTATION WORLDWIDE Recurrent Hepatocellular Carcinoma is a Problem We Need To Tackle A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, et al. Hepatology 2007;45: Orthotopic liver transplantation (OLT) is the only curative therapy of HCC with underlying cirrhosis, but due to HCC metastasis and recurrence, its benefit is limited to a small population who meet the strict selection criteria. We previously reported that Licartin ([ 131 I]mAb HAb18G/CD147) was safe and effective in treating HCC patients, and its antigen, HAb18G/ CD147, was closely related to HCC invasion and metastasis. Here, we reported a randomized controlled trial to assess the post-olt antirecurrence efficacy of Licartin in advanced HCC patients. We randomized 60 post-olt patients with HCC, who were at tumor stage 3/4 and outside the Milan criteria before OLT, into 2 groups. Three weeks after OLT, the treatment group received 15.4 MBq/kg of Licartin, while the control group received placebo intravenously for 3 times with an interval of 28 days. At 1-year follow-up, the recurrence rate significantly decreased by 30.4% (P ) and the survival rate increased by 20.6% (P ) in the treatment group, compared with those in the control group. For the control group versus the treatment group, the hazard ratio for recurrence was 3.60 (95% confidence interval [CI], ) and that for death was 3.87 (95% CI, ). Licartin treatment also resulted in an earlier decreased AFP level and a longer time of normal AFP level than placebo (P ). No Licartin-related toxic effects were observed. Conclusion: Licartin is a promising drug for preventing post-olt tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT. HAb18G/CD147 can be a good drug target. The pre liver transplantation selection process for patients with hepatocellular carcinoma (HCC) is being continuously refined; yet, the problem of recurrent HCC remains. 1 In 1 study, recurrence was seen in approximately 15% of the patients transplanted for HCC, and most died. 2 Despite the use of either Milan or University of California at San Francisco criteria for selecting patients and allocating organs to recipients with HCC, preoperative imaging still understages 40%-55% of HCC tumors. 2,3 Thus, patients with HCC need to be re-evaluated after transplantation to check on the pathological stage of their tumors. Parfitt et al. 4 developed a pathological score for explanted livers to better predict recurrence. On the basis of this score, the investigators grouped their patients into 3 posttransplant risk categories for HCC recurrence: low ( 5%), intermediate (40%-65%), and high ( 95%). Other scoring systems will surely follow. Why rescore patients after transplantation for HCC recurrence? What can be done for patients who are found to be at high risk for HCC recurrence when they have already received a liver transplant? Should the surveillance schedule be modified in the different risk groups? Should the immunosuppressive medication be changed? Zhou et al. 5 reported on 36 patients with HCC being switched from tacrolimus to rapamycin. This small study, lacking statistical power, suggests that rapamycin-based immunosuppression may inhibit HCC recurrence. What should be done about treating patients at high risk for HCC recurrence? In this review, Xu et al. report on a randomized control trial using Licartin ([ 131 I]metuximab injection) to treat patients who underwent transplantation for HCC to prevent a recurrence. These authors previously reported on phase 1 and 2 trials with Licartin. 6 They enrolled in their study patients with stage 3 and 4 HCC (TNM classification) who were definitely outside the Milan criteria. They excluded patients with heart or kidney disease and bilirubin greater than 2.5 times the normal range. Sixty eligible patients who received donor livers from cadaver donors (voluntarily donated) were randomized between receiving treatment or receiving a placebo. All were single-blinded to the treatment. Thirty treated patients received Licartin 3 times at intervals of 28 days starting in the fourth week after the transplant. All patients received tacrolimus or cyclosporine A, mycophenolate mofetil, and prednisone. All patients were followed with liver ultrasonography, alpha-fetoprotein levels every 2 weeks, and computed tomography scans monthly. With a median follow-up of 12.3 months, 17 patients (57.1%) receiving the placebo and 8 receiving Licartin (26.7%) had tumor recurrence. This was a significant difference in the recurrence (P ). There was also a significant difference in survival between the 2 groups. There were no reported adverse events related to the Licartin treatment. Xu et al. concluded that Licartin is a promising drug to prevent HCC recurrence following liver transplantation. To the authors knowledge, this was the first prospective study evaluating antibody radioimmunotherapy for the prevention of HCC recurrence. Other studies with Abbreviation: HCC, hepatocellular carcinoma. DOI /lt Published online in Wiley InterScience ( American Association for the Study of Liver Diseases.
2 1058 LIVER TRANSPLANTATION WORLDWIDE similar or different treatment options are desperately needed to give hope to patients with high risk for HCC recurrence. 1. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007;13: Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006;81: Reddy MS, Manas DM. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2007;83: Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 2006;12: Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006;65: Reexamining Old Techniques from a New Perspective Spatulated end-to-end bile duct reconstruction in orthotopic liver transplantation. Buczkowski AK, Schaeffer DF, Kim PT, Ho SG, Yoshida EM, Steinbrecher UP, et al. Clin Transplant 2007;21:7-12. Biliary complications continue to be a major source of morbidity following orthotopic liver transplantation. The aim of this study was to analyze the incidence and management of biliary complications related to the technique of bile duct reconstruction. The patients were stratified into two groups: group I (n 39) had bile duct reconstruction performed by an end-to-end single interrupted suture choledochocholedochostomy (EE-CDCD) and group II (n 38) had a spatulated end-to-end CDCD (spee-cdcd) reconstruction; both groups had an intraductal stent. The groups were similar in age, gender, liver transplant indications and Pugh score. Ten biliary complications (26%), including five bile leaks (13%) and five biliary strictures (13%), were observed in the EE-CDCD group, while one biliary stricture (2.6%) occurred in the spee-cdcd group (p 0.05). Subsequent imaging studies and endoscopic retrograde cholangiopancreatography were performed less often in patients undergoing spee- CDCD reconstruction (p 0.05). The technique of a spatulated end-to-end bile duct reconstruction provides a significant improvement in lowering biliary complication rates in liver transplant patients. Despite the modest number of cases in this study this technique shows promise and has become the technique of choice in our institution. The ever-increasing focus on quality in healthcare requires that we, as transplant surgeons, relook at how we have always practiced our art. Striving to improve outcomes for our transplant patients has always been integral to the transplantation field, but now new concepts such as root cause analysis, pay for performance, objective skill assessment, lean methods, and cumulative sum are slowly infiltrating our discipline. 1,2 This will require learning a new language and revisiting some very common practices. One of the basic techniques in liver transplantation is management of the bile duct. Englesbe et al. 3 reviewed how the prevention of biliary complications following liver transplantation is vital to transplant surgical quality improvement. These authors showed how surgical improvement initiatives are a sound financial investment. A significant cause of negative financial margins in the investigators hospital was biliary leak following liver transplantation. 3 Payors benefited even more when patients did not have a biliary leak. With financial incentives to both hospitals and payors to prevent transplant complications, transplant programs will be mandated to evaluate how they conduct their routine transplant techniques. In this review, Buczkowski et al. revisit their technique of bile duct reconstruction in orthotopic liver transplantation. They report on the surgical method of spatulated end-to-end choledochocholedochostomy versus an end-to-end method without spatulation. Over a 2-year period, 39 patients (group I) were treated with the end-to-end method without spatulation, and 38 patients (group II) received spatulation. Both groups had intraductal stents. Retrospective data were collected for group I, and prospective data were collected for group II. There were no differences in the donor characteristics between groups. Ten biliary complications (26%), including 5 bile leaks and 5 strictures, occurred in group I, with only 1 biliary stricture (2.6%) occurring in group II. The difference was significant (P 0.05). Certainly this method is not new, with 1 of the first reports on it having appeared in However, there can be no argument for the relevance of this report in today s quality climate. The current focus on quality will require that some very routine management practices be revisited. We will need objective reasons why we do something instead of the phrase because we have always done it that way. Striving to improve patient outcomes will continue to be integral to transplantation, but a new language to include such terms as financial margins and variance in practice skills will need to be adopted.
3 LIVER TRANSPLANTATION WORLDWIDE Perkins JD, Levy AE, Duncan JB, Carithers RL Jr. Using root cause analysis to improve survival in a liver transplant program. J Surg Res 2005;129: Axelrod DA, Guidinger MK, Metzger RA, Wiesner RH, Webb RL, Merion RM. Transplant center quality assessment using a continuously updatable, risk-adjusted technique (CUSUM). Am J Transplant 2006;6: Englesbe MJ, Dimick J, Mathur A, Ads Y, Welling TH, Pelletier SJ, et al. Who pays for biliary complications following liver transplant? A business case for quality improvement. Am J Transplant 2006;6: Neuhaus P, Blumhardt G, Bechstein WO, Steffen R, Keck H. Side-to-side anastomosis of the common bile duct is the method of choice for biliary tract reconstruction after liver transplantation. Transplant Proc 1990;22:1571. Computed Tomography Scanning Detecting Esophageal Varices Esophageal varices in patients with cirrhosis: multidetector CT esophagography comparison with endoscopy. Kim SH, Kim YJ, Lee JM, Choi KD, Chung YJ, Han JK, et al. Radiology 2007;242: Purpose: To evaluate the use of multidetector computed tomographic (CT) esophagography to grade esophageal varices and differentiate between varices at low risk and those at high risk for bleeding, with endoscopy as the reference standard. Materials and Methods: This study was approved by the institutional review board; all subjects gave informed consent. Ninety patients with cirrhosis (65 men, 25 women; mean age, 54.8 years; range, years) were prospectively enrolled and underwent endoscopy and CT esophagography. Esophageal varices were graded independently at endoscopy by two endoscopists. CT esophagograms were interpreted retrospectively with a four-point scale by two radiologists blinded to other findings. Interobserver agreement between each radiologist and endoscopist was determined; endoscopic and CT esophagographic grades of esophageal varices were correlated. Radiologist performance for differentiation between low- and high-risk varices for bleeding on the basis of morphology at endoscopy was evaluated with receiver operating characteristic analysis. Patients were interviewed to determine acceptance at both examinations. Results: Thirty-seven of 90 patients had grade 0, 23 had grade 1, 18 had grade 2, and 12 had grade 3 esophageal varices. Thus, 60 patients were determined to be in a low-risk group and 30 in a high-risk group for variceal bleeding at endoscopy. There was almost perfect agreement in grading esophageal varices between endoscopists. There was close correlation (P 0.001) and substantial agreement between endoscopic and CT esophagographic grades. Radiologist performance for differentiating between low- and high-risk varices was (area under receiver operating characteristic curve). Patient interview results revealed that CT esophagography had better acceptance than did endoscopy (P 0.001). Conclusion: Use of CT esophagography allows grading of esophageal varices and differentiation between lowand high-risk varices and shows better patient acceptance than does endoscopy. Evaluating prospective liver transplant patients includes screening for hepatocellular carcinoma (HCC) with computed tomography (CT) scanning and looking for esophageal varices with endoscopy. The presence of HCC can determine the extent of a patient s treatment, which can range from no transplantation to extra allocation points and transplantation sooner. A patient with varices that are at high risk for bleeding can be treated with beta blockers or undergo endoscopic variceal ligation. A single procedure that could adequately screen for both conditions has the potential for being cost-effective and more patient friendly and shortening the time for the pretransplant evaluation. CT scanning has been routinely used for HCC evaluation. In this article, S. H. Kim et al. report on the use of multidetector CT esophagography to grade esophageal varices and differentiate between varices with low and high risk for bleeding. Endoscopy was used as the reference standard, with digital images graded by 2 endoscopists. All patients were assigned to either a low-risk group or a high-risk group for bleeding. Multidetector CT esophagography with a 16-detector CT scanner (Sensation 16, Siemens Medical Systems, Forchheim, Germany) was performed within 4 hours after endoscopy. Air insufflation was performed through a 16- French catheter inserted into the upper esophagus through the mouth. Air injection was performed at a rate of 700 ml/30 seconds from 12 seconds before scanning to the time at which the scanner passed the gastroesophageal junction. Three CT phases precontrast, arterial, and portal were performed. Three-dimensional images of the esophagus were rendered. Ninety patients with cirrhosis were studied who were undergoing an evaluation for HCC without concurrent gastrointestinal bleeding or prior endoscopic variceal ligation. The performance of the radiologists for differentiating varices at low and high risk for bleeding had a sensitivity of 90.5%-93.3% and a specificity of 81.7%- 96.7%. S. H. Kim et al. concluded that multidetector CT scanning could be an adequate screen for high-risk varices. Y. J. Kim et al. 1 reported on their experience using routine helical liver CT scanning for the detection of esophageal varices. Their detection rate with this method was 92% for large varices and 53%-60% for small varices. CT scanning can also reveal other abnormalities, including ascites, gastric varices, splenomegaly, and portal-systemic shunts. 2 The value of CT scanning seems certain with respect to screening for HCC; it might now be adequate in screening for esophageal varices as well. Further study is needed in the liver transplant population to determine the cost effectiveness of multidetector CT esophagography. If nothing else, 1 screening
4 1060 LIVER TRANSPLANTATION WORLDWIDE instead of 2 would certainly offer a time advantage in shortening the pretransplantation evaluation process. 1. Kim YJ, Raman SS, Yu NC, To o KJ, Jutabha R, Lu DS. Esophageal varices in cirrhotic patients: evaluation with liver CT. AJR Am J Roentgenol 2007;188: Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, et al. High prevalence of spontaneous portalsystemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005;42: Cirrhotic Cardiomyopathy: Multiple Reviews Cirrhotic cardiomyopathy. Milani A, Zaccaria R, Bombardieri G, Gasbarrini A, Pola P. Dig Liver Dis 2007;39: Decompensated liver cirrhosis is characterized by a peripheral vasodilation with a low-resistance hyperdynamic circulation. The sustained increase of cardiac work load associated with such a condition may result in an inconstant and often subclinical series of heart abnormalities, constituting a new clinical entity known as cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy is variably associated with baseline increase in cardiac output, defective myocardial contractility and lowered systo-diastolic response to inotropic and chronotropic stimuli, down-regulated -adrenergic function, slight histo-morphological changes, and impaired electric recovery ability of ventricular myocardium. Cirrhotic cardiomyopathy is usually clinically latent or mild, likely because the peripheral vasodilation significantly reduces the left ventricle after-load, thus actually auto-treating the patient and masking any severe manifestation of heart failure. In cirrhotic patients, the presence of cirrhotic cardiomyopathy may become unmasked and clinically evident by certain treatment interventions that increase the effective blood volume and cardiac preload, including surgical or transjugular intrahepatic porto-systemic shunts, peritoneo-venous shunts (LeVeen) and orthotopic liver transplantation. Under these circumstances, an often transient overt congestive heart failure may develop, with increased cardiac output as well as right atrial, pulmonary artery and capillary wedge pressures. Several recent reviews on cirrhotic cardiomyopathy have been published, including this review by Milani et al. 1-3 Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with cirrhosis characterized by blunted contractile responsiveness to stress and/or altered diastolic relaxation with electrophysiological abnormalities, in the absence of known cardiac disease, as stated by a consensus of international experts during the World Congress of Gastroenterology held in Montreal in ,4 Cirrhotic cardiomyopathy was also reviewed in Liver Transplantation in Is there anything new in the interaction between liver transplantation and cirrhotic cardiomyopathy? As Milani et al. point out, cirrhotic cardiomyopathy is usually clinically latent or mild, likely because the peripheral vasodilation significantly reduces the left ventricle after-load, thus actually auto-treating the patient and masking any severe manifestation of heart failure. This situation can continue until major stresses on the cardiovascular system, such as liver transplantation, infections, and insertion of transjugular intrahepatic portosystemic shunts, unmask the presence of cirrhotic cardiomyopathy. 2 The course of a patient rapidly developing severe congestive heart failure soon after successful liver transplantation without a perioperative myocardial infarction is not uncommon. Such a patient requires several days in the intensive care unit, sometimes expiring. Can patients such as these be identified before transplantation? Even though patients with cirrhotic cardiomyopathy are reported to have a baseline increased cardiac output but blunted ventricular response to stimuli, systolic and/or diastolic dysfunction, absence of overt left ventricular failure at rest, electrophysiological abnormalities including a prolonged QT interval on electrocardiography, and chronotropic incompetence, a gold standard to identify patients at risk prior to transplantation is lacking. 2,5 It has been suggested that echocardiography or dynamic magnetic resonance cardiac imaging to evaluate diastolic function may be the best available screening test. 2 Most investigators have concluded that there are no firm diagnostic criteria that can be identified before transplantation. A recent review found no discernibly different cardiac workup factors following transplantation between patients who developed cirrhotic cardiomyopathy and those who did not (E. Y. Chan, personal communication; March 15, 2007). In addition, the prevalence of cirrhotic cardiomyopathy is unknown because of the difficult diagnostic parameters. Milani et al. conclude that the management of cirrhotic cardiomyopathy is largely empirical because of the paucity of literature. Cirrhotic cardiomyopathy does appear reversible after liver transplantation. 2,6 Liu and Lee 7 reported that liver transplantation reverses the alterations of increased ventricular wall thickness, diastolic dysfunction, and abnormal systolic response to stress present in patients with cirrhotic cardiomyopathy. 7 Following a prolonged posttransplant recovery period, it appears that most patients survive. The bottom line is that patients who develop heart failure following liver transplantation secondary to cirrhotic cardiomyopathy still cannot be identified before transplantation, and there is no particular treatment for these patients. As is so often the case, the final conclusion from all the recent reviews is that more studies are needed.
5 LIVER TRANSPLANTATION WORLDWIDE Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario. J Gastroenterol Hepatol 2007;22: Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007;2: Pozzi M, Ratti L, Guidi C, Milanese M, Mancia G. Potential therapeutic targets in cirrhotic cardiomyopathy. Cardiovasc Hematol Disord Drug Targets 2007;7: Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989;151: Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;6(suppl 1, pt 4):S44 S Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, et al. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998;4: Liu H, Lee SS. What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology 2005;42: James D. Perkins, M.D., Special Editor Liver Transplantation Worldwide University of Washington Medical Center Seattle, WA
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute variceal bleeding management of, 251 262 balloon tamponade of esophagus in, 257 258 endoscopic therapies in, 255 257. See also Endoscopy,
More informationCurrent status of hepatic surgery in Korea
Korean J Hepatol. 2009 Dec; 15(Suppl 6):S60 - S64. DOI: 10.3350/kjhep.2009.15.S6.S60 Current status of hepatic surgery in Korea Kyung Sik Kim Department of Surgery, Severance Hospital, Yonsei University
More informationDetection of Esophageal Varices Using CT and MRI
Dig Dis Sci (2011) 56:2696 2700 DOI 10.1007/s10620-011-1660-8 ORIGINAL ARTICLE Detection of Esophageal Varices Using CT and MRI Michael J. Lipp Arkady Broder David Hudesman Pauline Suwandhi Steven A. Okon
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationA study of cardiac dysfunction in cirrhotics
Original Research Article A study of cardiac dysfunction in cirrhotics Venkata Reddy S., Thankappan K.R. *, Srinivas M.G., Sridhar K, Ajith Roni Department of Medical Gastroenterology, Narayana Medical
More informationMichele Bettinelli RN CCRN Lahey Health and Medical Center
Michele Bettinelli RN CCRN Lahey Health and Medical Center Differentiate the types of varices Identify glue preparations utilized when treating gastric varices Review the process of glue administration
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationVIRTUAL UPPER GASTROINTESTINAL ENDOSCOPY
UnitedHealthcare Commercial Medical Policy VIRTUAL UPPER GASTROINTESTINAL ENDOSCOPY Policy Number: GAS018 Effective Date: December 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationVIRTUAL UPPER GASTROINTESTINAL ENDOSCOPY
UnitedHealthcare Oxford Clinical Policy VIRTUAL UPPER GASTROINTESTINAL ENDOSCOPY Policy Number: DIAGNOSTIC 045.9 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 APPLICABLE
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationVIRTUAL UPPER GASTROINTESTINAL ENDOSCOPY
MEDICAL POLICY VIRTUAL UPPER GASTROINTESTINAL ENDOSCOPY Policy Number: 2013T0400H Effective Date: October 1, 2013 Table of Contents COVERAGE RATIONALE... BACKGROUND... CLINICAL EVIDENCE... U.S. FOOD AND
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationOptimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)
XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACLF. See Acute-on-chronic liver failure (ACLF) Acute kidney injury (AKI) in ACLF patients, 967 Acute liver failure (ALF), 957 964 causes
More informationThe authors have declared no conflicts of interest.
Diagnostic Accuracy of Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography Findings in the Postorthotopic Liver Transplant Population Authors: *Ashok Shiani,
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationInnovations in HCC Imaging: MDCT/MRI
Innovations in HCC Imaging: MDCT/MRI Anthony E. Cheng, M.D. Cardinal MRI Center Cardinal Santos Medical Center, Wilson Street, San Juan Innovations in HCC Imaging: Goals/Objectives MDCT/MRI Learn the diagnostic
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationCAN HEART RATE AND QTc DURATION BE USED AS A MARKER OF CIRRHOTIC CARDIOMYOPATHY? A CASE CONTROL STUDY
ORIGINAL ARTICLE CAN HEART RATE AND QTc DURATION BE USED AS A MARKER OF CIRRHOTIC CARDIOMYOPATHY? A CASE CONTROL STUDY 1 2 3 Shahid Mumtaz Abbasi, Yasmin Aamir, Sumera Gul, 4 5 Nayyar Yaqoob, M Saleem
More informationThe Heart in Concert: Do Other Organs Matter? The Liver
The Heart in Concert: Do Other Organs Matter? The Liver Pascal de Groote CHRU Lille France DECLARATION OF CONFLICT OF INTEREST I have no conflict of interest with this presentation Impact of liver disease
More informationUpdate in abdominal Surgery in cirrhotic patients
Update in abdominal Surgery in cirrhotic patients Safi Dokmak HBP department and liver transplantation Beaujon Hospital, Clichy, France Cairo, 5 April 2016 Cirrhosis Prevalence in France (1%)* Patients
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationSupplementary Digital Content
Geissler et al: Sirolimus and Hepatocellular Carcinoma in Liver Transplantation Page 1 of 10 Supplementary Digital Content Supplementary Table 1. Surgical procedures used Total Transplant technique Piggy
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationHow to apply HCC prediction models to practice?
How to apply HCC prediction models to practice? Department of Internal Medicine, Keimyung University School of Medicine Woo Jin Chung HCC prediction models 독특하게간세포암환자들의생존은암의진행상태뿐아니라기저간기능의중증정도에영향을받는특성이있다.
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationVirtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationClinical Study The Impact of the Introduction of MELD on the Dynamics of the Liver Transplantation Waiting List in São Paulo, Brazil
Transplantation, Article ID 219789, 4 pages http://dx.doi.org/1.1155/214/219789 Clinical Study The Impact of the Introduction of MELD on the Dynamics of the Liver Transplantation Waiting List in São Paulo,
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationDobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis
The Korean Journal of Hepatology 2010;16:376-382 DOI: 10.3350/kjhep.2010.16.4.376 Original Article Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis Moon Young
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationUniversity of Colorado Health Sciences Center, Denver Colorado ******************** ******************
University of Colorado Health Sciences Center, Denver Colorado ******************** 1988-2005 ****************** Disclosures No disclosures Case 53 M presents with sudden onset of upper abdominal pain
More informationEditorial Process: Submission:07/25/2018 Acceptance:10/19/2018
RESEARCH ARTICLE Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018 Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand Jitrapa
More informationWhat Is the Real Gain After Liver Transplantation?
LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationSandipan Ghose, Md. Azizul Hoque, Md. Khalilur Rahman, Mohd. Harun-or-Rashid
Sandipan Ghose, Md. Azizul Hoque, Md. Khalilur Rahman, Mohd. Harun-or-Rashid Liver cirrhosis may be defined as a diffuse process characterized by fibrosis and conversion of normal liver architecture into
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationLiver Transplantation
Liver Transplantation Dr Mathew Jacob - MRCS FRCS CCT (UK) Lead Consultant HPB/Transplant Surgeon Aster Integrated Liver Care Program AsterMedcity, kochi, kerala, India mathew@transplantationliver.com
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationLiver Transplantation: What an Internist Needs to Know
Liver Transplantation: What an Internist Needs to Know Thomas Kerr, M.D. Ph.D. University of Texas Southwestern Medical Center Digestive and Liver Diseases This is to acknowledge that Thomas Kerr, M.D.
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationIn- and exclusion criteria
In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationDRAFT. Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect. What is a transjugular intrahepatic portosystemic shunt?
UW MEDICINE PATIENT EDUCATION Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect This handout explains a transjugular intrahepatic portosystemic shunt and what to expect when
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationTIPS. D Patch Royal Free Hospital London UK
TIPS D Patch Royal Free Hospital London UK TIPS Technique Ascites Budd Chiari Variceal Bleeding Historical Experimental Development 1967 Piccone Shunt between recanalized umbilical vein and saphenous
More informationAn assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery
The American Journal of Surgery (2012) 203, 589 593 North Pacific Surgical Association An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery Marlin Wayne Causey,
More informationThe Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease
LIVER TRANSPLANTATION 14:235-239, 2008 ORIGINAL ARTICLE The Effect of Liver Transplantation on Autonomic Dysfunction in Patients with End-Stage Liver Disease Elizabeth J. Carey, Manjushree Gautam, 3 Timothy
More informationShould Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores < 14 Be Avoided? A Decision Analysis Approach
LIVER TRANSPLANTATION 15:242-254, 2009 ORIGINAL ARTICLE Should Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores < 14 Be Avoided? A Decision Analysis Approach James D. Perkins,
More informationAlice Fung, MD Oregon Health and Science University
Alice Fung, MD Oregon Health and Science University Disclosure Comments The speaker Alice Fung, MD Has relevant financial relationships to disclose. Received honorarium from (Guerbet). This individual
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationObservational Medical Outcomes Partnership
Implications of Health Outcomes of Interest Definitions: Acute Liver Injury Case Study Judy Racoosin, Patrick Ryan on behalf of OMOP Research Team Observational Medical Outcomes Partnership Established
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationTranjugular Intrahepatic Portosystemic Shunt
Tranjugular Intrahepatic Portosystemic Shunt Christopher Selhorst July 25, 2005 BIDMC Radiology Overview Portal Hypertension Indications, Contraindications The Procedure Case Review Complications Outcomes
More informationGemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis
GE Healthcare Gemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis CT clinical case study lesion characterization Desiree Morgan, MD Vice Chair of Clinical Research Professor
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationVentricular arrhythmia in patients with prolonged QT interval during liver transplantation -two cases report-
Case Report Korean J Anesthesiol 2014 December 67(6): 416-420 http://dx.doi.org/10.4097/kjae.2014.67.6.416 Ventricular arrhythmia in patients with prolonged QT interval during liver transplantation -two
More informationPost-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options
Post-operative complications following hepatobiliary surgery: imaging findings and current radiological treatment options Poster No.: C-1501 Congress: ECR 2015 Type: Educational Exhibit Authors: A. Hadjivassiliou,
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationA LEADER IN ADVANCED ENDOSCOPY AND HEPATOBILIARY SURGERY
A LEADER IN ADVANCED ENDOSCOPY AND HEPATOBILIARY SURGERY St. Peter s Hospital Advanced Endoscopy & Hepatobiliary Center Welcome The St. Peter s Hospital Advanced Endoscopy & Hepatobiliary Center is a leader
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationIntrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1
Intrahepatic Sarcomatoid Cholangiocarcinoma with Portal Vein Thrombosis: A Case Report 1 Jae-Hoon Lim, M.D., Jin Woong Kim, M.D., Suk Hee Heo, M.D., Yong Yeon Jeong, M.D., Heoung Keun Kang, M.D. A 53-year-old
More informationManagement of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationGastroenterology. Certification Examination Blueprint. Purpose of the exam
Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist
More informationResearch Article Safety and Yield of Diagnostic ERCP in Liver Transplant Patients with Abnormal Liver Function Tests
Diagnostic and erapeutic Endoscopy, Article ID 314927, 5 pages http://dx.doi.org/10.1155/2014/314927 Research Article Safety and Yield of Diagnostic ERCP in Liver Transplant Patients with Abnormal Liver
More informationMR Elastography of Liver
MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018
More informationFollowing the introduction of adult-to-adult living
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION Liver Transplant Recipient Survival Benefit with Living Donation in the Model for Endstage Liver Disease Allocation Era Carl L. Berg, 1 Robert M. Merion, 2 Tempie
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationPortogram shows opacification of gastroesophageal varices.
Portogram shows opacification of gastroesophageal varices. http://clinicalgate.com/radiologic-hepatobiliary-interventions/ courtesyhttp://emedicine.medscape.com/article/372708-overview DR.Thulfiqar Baiae
More information(Received for Publication: March 24, 2015) Key words portal venous pressure, major hepatectomy, liver
55 Original Article J. St. Marianna Univ. Vol. 6, pp. 55 61, 2015 Usefulness of Intraoperative Measurement of Portal Venous Pressure for Confirming the Most Appropriate Hepatectomy in Patients with Borderline
More informationLiving donor liver transplantation for hepatocellular carcinoma in Seoul National University
Original Article on Liver Transplantation for Hepatocellular Carcinoma Living donor liver transplantation for hepatocellular carcinoma in Seoul National University Suk Kyun Hong, Kwang-Woong Lee, Hyo-Sin
More informationORIGINAL ARTICLE Gastroenterology & Hepatology INTRODUCTION
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.8.1207 J Korean Med Sci 2013; 28: 1207-1212 The Model for End-Stage Liver Disease Score-Based System Predicts Short
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationLiver Transplantation
1 Liver Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr History Development of Liver transplantation
More informationGeographic Differences in Event Rates by Model for End-Stage Liver Disease Score
American Journal of Transplantation 2006; 6: 2470 2475 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant
More information